In Depth 26 Jan 2026 A clearer path to relief: sinusitis treatments on the way Emerging sinusitis treatments include monoclonal antibodies to tackle the unmet medical needs of patients. January 26, 2026 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Dec 2025 Eight of the biggest immunology and inflammation (I&I) deals in 2025 Discover eight of the biggest immunology and inflammation (I&I) deals in 2025, from early-stage collaborations to late-stage licensing deals. December 17, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 26 Sep 2025What’s next in immunology & inflammation R&D: The trends to watch This week’s guest is Joseph Ferner of Inpart, the author of a new R&D Trends Report on Immunology and Inflammation. Together we discussed the research landscape September 26, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Reports Produced by Inpart 31 Jul 2025Immunology & inflammation R&D trends and breakthrough innovations Providing scientific decision-makers with a roadmap of high-impact I&I opportunities, emerging technologies, and potential future partners. July 31, 2025 Share WhatsApp Twitter Linkedin Email Produced by Inpart
Podcast 18 Jul 2025Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy This week, I talked to Niels Riedemann, CEO and Founder of InflaRx, about his company’s first-in-class approach to fighting inflammation. July 18, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 4 Jul 2025Persica Pharmaceuticals is treating the cause of chronic lower back pain, not just the symptoms Our guest today, Steve Ruston of Persica Pharmaceuticals is developping a treatment targeting the cause of chronic lower back pain: the bacterial infection. July 4, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 27 May 2025 Interleukin therapeutics: 9 companies to follow in 2025 Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses. Over the years, companies have explored interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many early attempts were held back […] May 27, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 10 Jan 2025Fighting pain with non-opioid drugs In the first episode of 2025, we talk about non-opioid pain drugs with Brixton Biosciences. January 10, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 26 Nov 2024 Seven miRNA-focused companies pioneering new therapies in 2024 Delve into the field of miRNA with seven companies with miRNA-focused candidates in the pipeline in 2024, from oncology to neurodegeneration. November 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 1 Nov 2024The immunometabolism landscape To talk about immunometabolism, our guest on the podcast this week is CEO of Sitryx Therapeutics, Iain Kilty. November 1, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 16 Oct 2024 JAK inhibitors: Are they a good option for treating inflammatory diseases and cancer? Find out more about JAK inhibitors and whether they are a good option for treating inflammatory diseases and cancer. October 16, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2024 Resolution Therapeutics raises $85 million to advance its macrophage therapy Find out about Resolution Therapeutics’ macrophage therapy, as it just raised $85 million in a series B round. October 3, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email